Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- LUPUS27(5) · pp.753 · 2018
- 피인용
- Web of Science 16Scopus 18
- FWCI (Scopus)
- 0.92
- JCR IF
- JCR 2017 2.969
- ISSN
- 0961-2033
저자
- 이승근제1저자교신저자Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea
- 박은경Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea
- 박지혜Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea
- 권성민Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea
- 김윤경Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
- 김근태Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
초록
We aimed to analyze compliance and persistence with hydroxychloroquine (HCQ) in real practice and identify risk factors for poor adherence in South Korean patients with systemic lupus erythematosus (SLE). This retrospective longitudinal study evaluated 235 SLE patients in whom oral HCQ was newly started from 2002 to 2016 at a tertiary hospital in South Korea. Compliance was assessed using one-year medication possession ratio (MPR) and non-compliance was defined as a one-year MPR<0.8. Persistence was determined as the time from HCQ treatment initiation to discontinuation without interruption for 56 days. The mean one-year MPR of HCQ was 0.88 and the frequency of non-compliance was 19.9%. During the study period, 115 (48.9%) patients discontinued HCQ and forgetfulness and/or carelessness (73%) were the most common reason for HCQ non-persistence, followed by adverse events (10.4%), unknown factors (10.4%), and pregnancy (6.1%). Median duration until HCQ discontinuation was 55.1 months and the one-year persistence rate to HCQ was 0.8. SLE Disease Activity Index 2000 (SLEDAI-2K) <6 was a significant risk factor for non-compliance (OR=2.98, p=0.001) and non-persistence (HR=1.55, p=0.046) with HCQ after adjusting confounding factors. However, HCQ adherence was not associated with the dose of HCQ or concomitant immunosuppressive medications. Our data showed that overall adherence to HCQ in SLE patients was suboptimal in real practice and SLEDAI-2K score <6 was a risk factor for poor adherence, suggesting the need to improve adherence with HCQ treatment in SLE patients, especially in those with low disease activity.
키워드
Systemic lupus erythematosushydroxychloroquinemedication adherencecomplianceORAL BISPHOSPHONATESMEDICATION ADHERENCERETROSPECTIVE COHORTLONGITUDINAL COHORTYOUNG-ADULTSPREGNANCYRECOMMENDATIONSOSTEOPOROSISDISEASENONADHERENCE
식별자
- Scopus EID
- 2-s2.0-85044774838
- WoS UID
- 000429894300008



로그인
연구물 목록으로